Fight CRC Clinical Trial Finder
NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT04008030 |
TitleA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW ) | Phase
Phase 3
|
Date Added 2019-07-05 |
Location
California, United States
Colorado, United States Illinois, United States New York, United States Oregon, United States Pennsylvania, United States Texas, United States Virginia, United States Argentina Australia Austria Belgium Brazil Canada Chile China Czechia Denmark France Germany Greece Ireland Italy Japan Netherlands Norway Puerto Rico Romania Spain Turkey United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, cetuximab, fluorouracil, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSI-H/ MMRd
|
NCT ID NCT04003792 |
TitleTreatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM. | Phase
Phase 2
|
Date Added 2019-07-01 |
Location
Israel
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Bevacizumab, FOLFIRI Protocol, oxaliplatin |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03994601 |
TitleAn Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | Phase
Phase 1
|
Date Added 2019-06-21 |
Location
California, United States
Colorado, United States Maryland, United States Missouri, United States New Jersey, United States Argentina Canada Chile France Italy Spain |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BMS-986288, Nivolumab, Opdivo |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03990233 |
TitleA Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Phase
Phase 1
|
Date Added 2019-06-18 |
Location
Belgium
France |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BI 754091, BI 765063 |
Tags
MSS/ MMRp
|
NCT ID NCT03985891 |
TitleThe Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer | Phase
Phase 1/Phase 2
|
Date Added 2019-06-14 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03984578 |
TitleWindow of Opportunity Study in Colorectal Cancer | Phase
Phase 2
|
Date Added 2019-06-13 |
Location
Singapore
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Capecitabine/ 5-FU, CapeOX, Pembrolizumab, Eloxatin, Keytruda |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03983993 |
TitleNiraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2019-06-12 |
Location
Georgia, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Niraparib, panitumumab, Vectibix, Zejula |
Tags
MSS/ MMRp
|
NCT ID NCT03981146 |
TitleA Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer | Phase
Phase 2
|
Date Added 2019-06-10 |
Location
United Kingdom
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Nivolumab, Opdivo |
Tags
MSS/ MMRp
|
NCT ID NCT03977090 |
TitleGeptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2019-06-06 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Fruquintinib, Geptanolimab Injection, Elunate |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03970382 |
TitleA Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | Phase
Phase 1
|
Date Added 2019-05-31 |
Location
California, United States
Illinois, United States New York, United States Tennessee, United States Washington, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Suspended
|
Drugs
IL-2, NeoTCR-P1 adoptive cell therapy, Nivolumab |
Tags
MSS/ MMRp
|